BACKGROUND: Bacterial pneumonia risk is disproportionately high among those infected with HIV. This risk is present across all CD4(+) T-cell levels (TCLs), suggesting that additional factors govern susceptibility. This study examines CD8(+) TCLs and risk for HIV-associated bacterial pneumonia and all-cause mortality. METHODS: Demographic, clinical, and laboratory data were obtained for 885 HIV-infected women enrolled in the HIV Epidemiologic Research Study (HERS). Bacterial pneumonia cases were identified using clinical, microbiological, and radiographic criteria. CD8(+) TCLs were assessed at 6-month intervals. Statistical methods included Cox proportional hazards regression modeling and covariate-adjusted survival estimates. RESULTS: Relative to a referent CD8(+) TCL of 401-800 cells per cubic millimeter, risk for bacterial pneumonia was significantly higher when CD8(+) TCLs were <400 (hazard ratio 1.65, P = 0.017, 95% confidence interval 1.10 to 2.49), after adjusting for age, CD4(+) TCL, viral load, and antiretroviral use. There was also a significantly higher risk of death when CD8(+) TCLs were ≤400 cells per cubic millimeter (hazard ratio 1.45, P = 0.04, 95% confidence interval 1.02 to 2.06). Covariate-adjusted survival estimates revealed shorter time to pneumonia and death in this CD8(+) TCL category, and the overall associations of the categorized CD8(+) TCL with bacterial pneumonia and all-cause mortality were each statistically significant (P = 0.017 and P < 0.0001, respectively). CONCLUSIONS: CD8(+) TCL ≤400 cells per cubic millimeter was associated with increased risk for pneumonia and all-cause mortality in HIV-infected women in the HERS cohort, suggesting that CD8(+) TCL could serve as an adjunctive biomarker of pneumonia risk and mortality in HIV-infected individuals.
BACKGROUND:Bacterial pneumonia risk is disproportionately high among those infected with HIV. This risk is present across all CD4(+) T-cell levels (TCLs), suggesting that additional factors govern susceptibility. This study examines CD8(+) TCLs and risk for HIV-associated bacterial pneumonia and all-cause mortality. METHODS: Demographic, clinical, and laboratory data were obtained for 885 HIV-infectedwomen enrolled in the HIV Epidemiologic Research Study (HERS). Bacterial pneumonia cases were identified using clinical, microbiological, and radiographic criteria. CD8(+) TCLs were assessed at 6-month intervals. Statistical methods included Cox proportional hazards regression modeling and covariate-adjusted survival estimates. RESULTS: Relative to a referent CD8(+) TCL of 401-800 cells per cubic millimeter, risk for bacterial pneumonia was significantly higher when CD8(+) TCLs were <400 (hazard ratio 1.65, P = 0.017, 95% confidence interval 1.10 to 2.49), after adjusting for age, CD4(+) TCL, viral load, and antiretroviral use. There was also a significantly higher risk of death when CD8(+) TCLs were ≤400 cells per cubic millimeter (hazard ratio 1.45, P = 0.04, 95% confidence interval 1.02 to 2.06). Covariate-adjusted survival estimates revealed shorter time to pneumonia and death in this CD8(+) TCL category, and the overall associations of the categorized CD8(+) TCL with bacterial pneumonia and all-cause mortality were each statistically significant (P = 0.017 and P < 0.0001, respectively). CONCLUSIONS:CD8(+) TCL ≤400 cells per cubic millimeter was associated with increased risk for pneumonia and all-cause mortality in HIV-infectedwomen in the HERS cohort, suggesting that CD8(+) TCL could serve as an adjunctive biomarker of pneumonia risk and mortality in HIV-infected individuals.
Authors: D K Smith; D L Warren; D Vlahov; P Schuman; M D Stein; B L Greenberg; S D Holmberg Journal: Am J Epidemiol Date: 1997-09-15 Impact factor: 4.897
Authors: S L Melnick; R Sherer; T A Louis; D Hillman; E M Rodriguez; C Lackman; L Capps; L S Brown; M Carlyn; J A Korvick Journal: JAMA Date: 1994-12-28 Impact factor: 56.272
Authors: R E Hirschtick; J Glassroth; M C Jordan; T C Wilcosky; J M Wallace; P A Kvale; N Markowitz; M J Rosen; B T Mangura; P C Hopewell Journal: N Engl J Med Date: 1995-09-28 Impact factor: 91.245
Authors: Nadine Hartmann; Curtis McMurtrey; Michelle L Sorensen; Megan E Huber; Regina Kurapova; Fadie T Coleman; Joseph P Mizgerd; William Hildebrand; Mitchell Kronenberg; David M Lewinsohn; Melanie J Harriff Journal: Am J Respir Cell Mol Biol Date: 2018-06 Impact factor: 6.914
Authors: Sergio Serrano-Villar; Kunling Wu; Peter W Hunt; Judith J Lok; Raquel Ron; Talía Sainz; Santiago Moreno; Steven G Deeks; Ronald J Bosch Journal: EBioMedicine Date: 2022-05-26 Impact factor: 11.205
Authors: R F Hannaway; X Wang; M Schneider; S Slow; J Cowan; B Brockway; M R Schofield; X C Morgan; D R Murdoch; J E Ussher Journal: Clin Exp Immunol Date: 2019-10-24 Impact factor: 4.330
Authors: Cormac Cosgrove; James E Ussher; Andri Rauch; Kathleen Gärtner; Ayako Kurioka; Michael H Hühn; Krista Adelmann; Yu-Hoi Kang; Joannah R Fergusson; Peter Simmonds; Philip Goulder; Ted H Hansen; Julie Fox; Huldrych F Günthard; Nina Khanna; Fiona Powrie; Alan Steel; Brian Gazzard; Rodney E Phillips; John Frater; Holm Uhlig; Paul Klenerman Journal: Blood Date: 2012-12-18 Impact factor: 22.113
Authors: Adam Trickey; Margaret T May; Philipp Schommers; Jan Tate; Suzanne M Ingle; Jodie L Guest; M John Gill; Robert Zangerle; Mike Saag; Peter Reiss; Antonella d'Arminio Monforte; Margaret Johnson; Viviane D Lima; Tim R Sterling; Matthias Cavassini; Linda Wittkop; Dominique Costagliola; Jonathan A C Sterne Journal: Clin Infect Dis Date: 2017-09-15 Impact factor: 9.079